# Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

> **NCT06650332** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Metastatic HER2 Positive Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** cadonilimab
- **DRUG:** Trastuzumab
- **DRUG:** XELOX
- **DRUG:** Disitamab Vedotin
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT06650332
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2026-08-10
- **Final completion:** 2027-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650332, "Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06650332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*